DOTA-GA (tBu) 4

DOTA-GA (tBu) 4 stabilizes the attachment of radiometals to ligands. DOTA-GA (tBu) 4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA (tBu) 4 targets HER2-expressing breast and gastrointestinal cancer. [1][2]

Product Specifications

CAS Number

[306776-79-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Radionuclide-Drug Conjugates (RDCs)

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/dota-ga-tbu-4.html

Purity

99.30

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CCC(N1CCN(CCN(CCN(CC1)CC(OC(C)(C)C)=O)CC(OC(C)(C)C)=O)CC(OC(C)(C)C)=O)C(OC(C)(C)C)=O)O

Molecular Formula

C35H64N4O10

Molecular Weight

700.90

Precautions

H302, H315, H319, H335

References & Citations

[1]13962.pdf|[2]Westerlund K, et al. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. Mol Pharm. 2016;13 (5) :1668-1678.